Celldex Therapeutics (CLDX) Trading Up 7.5%

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) were up 7.5% during trading on Thursday . The stock traded as high as $0.31 and last traded at $0.31. Approximately 1,177,869 shares changed hands during mid-day trading, a decline of 46% from the average daily volume of 2,173,648 shares. The stock had previously closed at $0.29.

Several analysts have commented on CLDX shares. Cowen restated a “hold” rating on shares of Celldex Therapeutics in a report on Thursday, August 9th. HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Celldex Therapeutics in a report on Monday, November 12th. Finally, Jefferies Financial Group restated a “hold” rating on shares of Celldex Therapeutics in a report on Friday, August 10th. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $3.75.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.07. The company had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $2.08 million. Celldex Therapeutics had a negative return on equity of 51.88% and a negative net margin of 1,296.96%. Research analysts forecast that Celldex Therapeutics, Inc. will post -0.39 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Renaissance Technologies LLC lifted its stake in shares of Celldex Therapeutics by 2,633.4% in the 2nd quarter. Renaissance Technologies LLC now owns 4,220,687 shares of the biopharmaceutical company’s stock valued at $2,126,000 after purchasing an additional 4,066,273 shares in the last quarter. Acadian Asset Management LLC lifted its stake in shares of Celldex Therapeutics by 378.4% in the 2nd quarter. Acadian Asset Management LLC now owns 1,157,880 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 915,863 shares in the last quarter. GSA Capital Partners LLP acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at about $322,000. Paloma Partners Management Co lifted its stake in shares of Celldex Therapeutics by 5,357.8% in the 2nd quarter. Paloma Partners Management Co now owns 640,799 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 629,058 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Celldex Therapeutics by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,047,564 shares of the biopharmaceutical company’s stock valued at $2,728,000 after purchasing an additional 421,700 shares in the last quarter. 31.20% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Celldex Therapeutics (CLDX) Trading Up 7.5%” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.com-unik.info/2018/12/01/celldex-therapeutics-cldx-trading-up-7-5.html.

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.

Featured Story: How to use beta for portfolio diversification

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit